Startup | February 18, 2022
Evonik invests in start-up to improve patient recovery after open-chest surgery
Evonik invests in start-up to improve patient recovery after open-chest surgery
Evonik invests in start-up to improve patient recovery after open-chest surgery
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Apexxnar is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible for the majority of invasive disease and pneumococcal pneumonia
The entire integration and transition of the brands is expected to be completed by March 2022
These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
Subscribe To Our Newsletter & Stay Updated
